Radiopharmacy Advances Driving the Future of Theranostics
Uncover the benefits of radiopharmacy theranostics, bridging chemistry with targeted therapy for enhanced diagnostics.
Uncover the benefits of radiopharmacy theranostics, bridging chemistry with targeted therapy for enhanced diagnostics.
Q&A – Medical Imaging Modalities and Therapy explores innovative techniques and advancements in diagnostic and therapeutic imaging applications.
World Theranostics Day honours Dr. Hertz’s groundbreaking radioiodine therapy, transforming disease treatment globally since 1941.
225Ac-FPI-1434 advances in clinical trials, targeting IGF-1R in chemo-resistant solid tumors with promising results.
225Ac-DOTA-YS5 targets CD46 in prostate cancer, promising precision and effectiveness in therapy.
225Ac-DOTA-SP, a breakthrough in targeted alpha therapy, offers precise cancer treatment with minimal side effects, revolutionising oncological approaches.
Theranostics merges diagnostics and therapy, revolutionising personalised medicine with genetic profiling and targeted treatment strategies.
Lutetium radiopharmaceuticals significantly advance targeted cancer treatment and diagnostic capabilities.